Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tryptamine Therapeutics ( (AU:TYP) ) has issued an announcement.
Tryptamine Therapeutics Limited has released documents related to its 2025 Annual General Meeting, including a Letter of Access, AGM Notice of Meeting, and Proxy Form. The company’s ongoing clinical trials and developments in psilocin formulations position it as a significant player in the biotechnology sector, with potential implications for the treatment of various medical conditions and the advancement of psychedelic-assisted therapies.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on developing proprietary formulations of psilocin combined with psychotherapy to treat diseases with unmet medical needs. Their lead program, TRP-8803, is an IV-infused psilocin formulation aimed at improving the efficacy and experience of psychedelic therapy. The company has completed Phase 2a clinical trials for binge eating disorder and fibromyalgia, and is conducting trials for irritable bowel syndrome.
Average Trading Volume: 2,103,767
Technical Sentiment Signal: Buy
Current Market Cap: A$56.16M
For a thorough assessment of TYP stock, go to TipRanks’ Stock Analysis page.